Antonia Kalushkova Nair
- E-mail:
- antonia.kalushkova@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
Part of Haematologica, p. 567-577, 2024
- DOI for PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
- Download full text (pdf) of PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma
Part of Frontiers in Oncology, 2023
- DOI for The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma
- Download full text (pdf) of The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma
Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
Part of Cancer Research, p. 4586-4603, 2022
- DOI for Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
- Download full text (pdf) of Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
Part of EPIGENOMES, 2021
- DOI for One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
- Download full text (pdf) of One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Part of Cell Death and Disease, 2021
- DOI for A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
- Download full text (pdf) of A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
All publications
Articles in journal
Part of Haematologica, p. 567-577, 2024
- DOI for PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
- Download full text (pdf) of PVT1 interacts with the polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma
Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
Part of Cancer Research, p. 4586-4603, 2022
- DOI for Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
- Download full text (pdf) of Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
Part of EPIGENOMES, 2021
- DOI for One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
- Download full text (pdf) of One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies
A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
Part of Cell Death and Disease, 2021
- DOI for A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
- Download full text (pdf) of A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
GMYC: A Novel Inducible Transgenic Model of Group 3 Medulloblastoma
Part of Neuro-Oncology, p. 137-137, 2018
Part of Oncotarget, p. 10213-10224, 2017
- DOI for EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
- Download full text (pdf) of EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Part of Oncotarget, p. 103731-103743, 2017
- DOI for The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
- Download full text (pdf) of The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomain
Part of Oncotarget, p. 6809-6923, 2016
A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment
Part of Human Mutation, p. 964-975, 2016
- DOI for A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment
- Download full text (pdf) of A Role for the Chromatin-Remodeling Factor BAZ1A in Neurodevelopment
Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
Part of Journal of Experimental Medicine, p. 833-843, 2015
- DOI for Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
- Download full text (pdf) of Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia
Part of Blood, 2014
Part of Biochemical Pharmacology, p. 284-291, 2014
- DOI for AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia
- Download full text (pdf) of AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and a dose dependent reduction of kinase activity in acute myeloid leukemia
Part of Blood, 2014
Dormant SOX9-positive cells behind MYC-driven medulloblastoma recurrence
Articles, review/survey
The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma
Part of Frontiers in Oncology, 2023
- DOI for The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma
- Download full text (pdf) of The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma